Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 19;117(20):10970-10975.
doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.

Effective Treatment of Severe COVID-19 Patients With Tocilizumab


Effective Treatment of Severe COVID-19 Patients With Tocilizumab

Xiaoling Xu et al. Proc Natl Acad Sci U S A. .


After analyzing the immune characteristics of patients with severe coronavirus disease 2019 (COVID-19), we have identified that pathogenic T cells and inflammatory monocytes with large amount of interleukin 6 secreting may incite the inflammatory storm, which may potentially be curbed through monoclonal antibody that targets the IL-6 pathways. Here, we aimed to assess the efficacy of tocilizumab in severe patients with COVID-19 and seek a therapeutic strategy. The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People's Hospital were given tocilizumab in addition to routine therapy between 5 and 14 February 2020. The changes of clinical manifestations, computerized tomography (CT) scan image, and laboratory examinations were retrospectively analyzed. Fever returned to normal on the first day, and other symptoms improved remarkably within a few days. Within 5 d after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral blood, which decreased in 85.0% of patients (17/20) before treatment (mean, 15.52 ± 8.89%), returned to normal in 52.6% of patients (10/19) on the fifth day after treatment. Abnormally elevated C-reactive protein decreased significantly in 84.2% of patients (16/19). No obvious adverse reactions were observed. All patients have been discharged on average 15.1 d after giving tocilizumab. Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.

Keywords: COVID-19; SARS-CoV-2; cytokine storm; interleukin-6; tocilizumab.

Conflict of interest statement

The authors declare no competing interest.

Comment in

Similar articles

See all similar articles

Cited by 12 articles

  • Treatment of COVID-19 Patients with Convalescent Plasma.
    Salazar E, Perez KK, Ashraf M, Chen J, Castillo B, Christensen PA, Eubank T, Bernard DW, Eagar TN, Long SW, Subedi S, Olsen RJ, Leveque C, Schwartz MR, Dey M, Chavez-East C, Rogers J, Shehabeldin A, Joseph D, Williams G, Thomas K, Masud F, Talley C, Dlouhy KG, Lopez BV, Hampton C, Lavinder J, Gollihar JD, Maranhao AC, Ippolito GC, Saavedra MO, Cantu CC, Yerramilli P, Pruitt L, Musser JM. Salazar E, et al. Am J Pathol. 2020 May 27:S0002-9440(20)30257-1. doi: 10.1016/j.ajpath.2020.05.014. Online ahead of print. Am J Pathol. 2020. PMID: 32473109 Free PMC article.
  • Battling COVID-19: using old weapons for a new enemy.
    Kumar R, Gupta N, Kodan P, Mittal A, Soneja M, Wig N. Kumar R, et al. Version 2. Trop Dis Travel Med Vaccines. 2020 May 20;6:6. doi: 10.1186/s40794-020-00107-1. eCollection 2020. Trop Dis Travel Med Vaccines. 2020. PMID: 32454984 Free PMC article. Review.
  • Therapien gegen COVID-19 — ein Update : SARS-CoV-2-Pandemie.
    Müller T. Müller T. MMW Fortschr Med. 2020 May;162(10):20-23. doi: 10.1007/s15006-020-0505-9. MMW Fortschr Med. 2020. PMID: 32447695 Free PMC article. German.
  • Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy.
    Serzan MT, Kumar PN, Atkins MB. Serzan MT, et al. J Immunother Cancer. 2020 May;8(1):e000898. doi: 10.1136/jitc-2020-000898. J Immunother Cancer. 2020. PMID: 32434789 Free PMC article.
  • COVID Activated Emergency Scaling of Anesthesiology Responsibilities (CAESAR) ICU.
    Verdiner RE, Choukalas CG, Siddiqui S, Stahl DL, Galvagno SM Jr, Jabaley CS, Bartz RR, Lane-Fall M, Goff K, Sreedharan R, Bennett S, Williams GW, Khanna A. Verdiner RE, et al. Anesth Analg. 2020 May 7:10.1213/ANE.0000000000004957. doi: 10.1213/ANE.0000000000004957. Online ahead of print. Anesth Analg. 2020. PMID: 32398432 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

Supplementary concepts

LinkOut - more resources